These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Redefining C3 glomerulopathy: 'C3 only' is a bridge too far. Larsen CP; Walker PD Kidney Int; 2013 Feb; 83(2):331-2. PubMed ID: 23364589 [No Abstract] [Full Text] [Related]
48. The role of complement in C3 glomerulopathy. Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733 [TBL] [Abstract][Full Text] [Related]
49. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974 [TBL] [Abstract][Full Text] [Related]
50. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307 [TBL] [Abstract][Full Text] [Related]
52. C3 glomerulonephritis associated with ANCA positivity: a case report. Li L; Liu LQ; Yang YY; Hu ZX BMC Nephrol; 2021 Apr; 22(1):143. PubMed ID: 33882866 [TBL] [Abstract][Full Text] [Related]
53. Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. Chauvet S; Hauer JJ; Petitprez F; Rabant M; Martins PV; Baudouin V; Delmas Y; Jourde-Chiche N; Cez A; Ribes D; Cloarec S; Servais A; Zaidan M; Daugas E; Delahousse M; Wynckel A; Ryckewaert A; Sellier-Leclerc AL; Boyer O; Thervet E; Karras A; Smith RJH; Frémeaux-Bacchi V Kidney Int; 2022 Oct; 102(4):904-916. PubMed ID: 35752323 [TBL] [Abstract][Full Text] [Related]
56. Toward a working definition of C3 glomerulopathy by immunofluorescence. Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430 [TBL] [Abstract][Full Text] [Related]
57. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature. Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954 [TBL] [Abstract][Full Text] [Related]
58. Dense deposit disease in a child with febrile sore throat. Conti G; De Vivo D; Vitale A; Fede C; Santoro D Saudi J Kidney Dis Transpl; 2017; 28(4):925-928. PubMed ID: 28748900 [TBL] [Abstract][Full Text] [Related]
59. Recurrent C3 glomerulopathy after kidney transplantation. Obata S; Vaz de Castro PAS; Riella LV; Cravedi P Transplant Rev (Orlando); 2024 Apr; 38(2):100839. PubMed ID: 38412598 [TBL] [Abstract][Full Text] [Related]